Dr. Petrylak on Custirsen in Prostate Cancer

Daniel P. Petrylak, MD
Published: Monday, Mar 24, 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

Petrylak believes the science behind custirsen is good. Custirsen is a second-generation antisense inhibitor of clusterin​​, which may play a fundamental role in cancer cell survival and treatment resistance.

In a phase II trial, prostate cancer patients experienced a survival benefit when treated with custirsen. The results of the phase III trial should read out this year, Petrylak says.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

Petrylak believes the science behind custirsen is good. Custirsen is a second-generation antisense inhibitor of clusterin​​, which may play a fundamental role in cancer cell survival and treatment resistance.

In a phase II trial, prostate cancer patients experienced a survival benefit when treated with custirsen. The results of the phase III trial should read out this year, Petrylak says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x